Lab Notes: Endo acquires 6 product candidates for $35M; NiKang signs deal worth up to $218M
May 06, 2022 at 12:34 PM EDT
Marinus Pharmaceuticals resumes late-stage testing of its experimental seizure medication.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |